pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-28 |
Genomic Coordinates | chr3: 188688781 - 188688866 |
Synonyms | MIRN28, hsa-mir-28, miR-28, MIR28 |
Description | Homo sapiens miR-28 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-28-5p | |||||||||||||||||||||||||||
Sequence | 14| AAGGAGCUCACAGUCUAUUGAG |35 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||||||||
Editing Events in miRNAs |
|
DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SETD7 | ||||||||||||||||||||
Synonyms | KMT7, SET7, SET7/9, SET9 | ||||||||||||||||||||
Description | SET domain containing lysine methyltransferase 7 | ||||||||||||||||||||
Transcript | NM_030648 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SETD7 | |||||||||||||||||||||
3'UTR of SETD7 (miRNA target sites are highlighted) |
>SETD7|NM_030648|3'UTR 1 AAGGCCTGGCTTTGGGGTTCAGAGACCTGGAATAGAAACTTGGATCTATGCACTACGTTTATCTGACAATGGGACAACCA 81 GGGACTGCTCATGCTGTGACGTCACATCCTCTCACCATGCGTTAGCAACGACTTTCTCGCATACTAACTAGGTTTGACTG 161 TATTACTCATACCAGATTTAAAATTAGCTAGCCTTGCAACAACGTCCTACTGAGAGGTATTGTCGAGCATTTGACATAAG 241 ACAGCGTGATGTTCTTTGGTGGTTCAAGTCTAAATCTGTACCACATTCGGAGATGCCAAATGATTAGACTGAAACAGGGA 321 AACGGGGTTTTTCAGTCATTTTTAGTCAGTGGTTTTTCCATAGTGCTTTTTTCCTATGGCCAGTGCAAATTGTGTTAGCA 401 CACTTGCATATGTGCCGTATTAAGGGTTGACAATTACTACATCTTTATTCTCTAAATGTAGTATAATTTGCCTTTTAACC 481 TTTGATCTGTATCTTGCAATAGAATGGCTTTGGTTTTTTTCTTAGTAAATAGGAGCCCACTTCTAAAGTCATTTCACCCC 561 TCAGCCCTATTCTCTTTCTTAGATACCCTTTACAAGAGAAAACTTCCAAATGGATTTTTGCATCAATAGCAGTGTGTAGG 641 TCTCTCTGGTTCTTTCTATATCATCATTTTATTATTATGTCCTAATATAAAGTACTGGCTCATAGGGCCAGGGTATTATT 721 ATAGAATATTATTCTCGCATGTAAACAAAGATATCTTTGCTTTAAGATGTGAGAAGAAATGAATTTACTTTGTTTGCATT 801 AAGTTATGGAAGAGTTGTAATATATACTTTAAGAAAGAAGAGAAGAAAACTAGTATCTCTAAGCGGTAACTATGGCAATT 881 TTGCAATATTTTCAGTAGTGCTAGTAATTTTTTCCTCCTTGAGTACACATTAAATGTACATAACATAGCGCGGTCAGGCT 961 TGTGGCACAGTGCATTGAATTCAAAAGTCAAACAGCAAATTTGAATTCTAACAGAATTCAAAAAAAAATTTTTTTAGTCA 1041 GTACTACTAAGGCAGACACACTGATTACTAGGTACAAATCAAACCTTGATGCTAAAACTCTTCATCATTGTAATTTCAAA 1121 GCACTTACCTGCTTCAAAACATTGTAAACTAAGACTGAACACCTGTATAGTTTAAAAGCAACACTATCAATAGCATTTCA 1201 GCCATTTTGCCAGCCATGTGTAATCACAACTGCAGAAATAAGGAGAAAACCCCTGTTTTTTTAGTTTAGCTAATTAGATC 1281 TGTAACATCACTGGGATTGCTCTGAATGAATCCTGAGAGTTTTGTTTTTTATAAGCACCCTCACCACATGCCATAGCTTT 1361 GTCTCTTTTAGACACCTCGATGCAGCGGCTGGAAGGACTGGAGAGCAGCTGTTGTGCTGATCTGTAGCTGTCAGCTGTGA 1441 TTCCTGTCACCTGAGTCAGTTTGGTCTGGAAAGCGAAGGCCTTCCAAGCTGTAGCAGATAGTGAGCTCCAGCTGATGAGA 1521 GAAGGCTTCAGTGGAAGAAGAGTGAGGACATAGGCAGAAGGAAGTTTGCTATTTCTTGTCAGTTGCACATTGCTTTATGA 1601 AGACTACAACAAAAGTGCTTAATCCCAGGCTGCTCATGACTTTCATTTCAGGTGGCCCTTGGGCACATTGACAGAGTTGC 1681 CCTTCCCTTCTTTGCAACACCAGGCTTCCTAGAGCACCCGGTTGCATGCTTTGCAGCTAGGTGGCAGTGGTTTCAGGGAG 1761 ATCCAGTTGGATCCCTGCTTGAAAGCTTAAGCCAATGGTTCACCCATGAGAGGAAGTTGTCAGTGCTTCCAGGAAGATTG 1841 CCCACCAAAGGAACTGAATAGTTTTTAGATTTAAAGGCACCAGGATAGGGTCACTCTTACTCTGTAGAAAGAGACCGTTC 1921 TATACACTGTGACGGATGGGCCAGGGCCTCTGGACTTGCATTCTGATAGGTGCTTTAATTTAAATGTGCCCAAAGGGAGT 2001 GACTGTCTTCAGGAGAAAGATGGCTTGCATTAACCTCGATCAAGTGGGTTGTGCAGCCAGGTCAGGGAATGCGGTCAGGG 2081 AGAGGATAGTGCTGGTCATGCCCCCGATGCAGCTATGCTCTGAATGATTTCATTCCTGAGAGTGATAGCATTCTGGTCCT 2161 GGCTGCAGTGGGGTACAATTTACGTCCTAAGTGGGGGCTACTCTAATTATCCCATTCAAATGGAATTTTTTTCAAAATTG 2241 GATAGAAGGAATTGAAGAGTTGTAAGTAGTGATTAGTCTGCTAATCAGTTCTTCAGATGAGATATTGAATGGTAACACTC 2321 TGAGCTTAAAACTCAGCAGTGTGTCTGTGACCTCCACGCAAATCAGAGGAAGCAATGCATCCACGCTGAGCCTCACCATG 2401 TCTTCCTCCCAACTCTCTTCATACTCTCTGTGTCTTCCAGCTCTTCTTTCTCTGGCCGGCTCTCTTTCCTCTTCTCTCTG 2481 CATATGTGAGAACGCCTGGGCATCCTGGGTAACAGCAGCCCCAGCTGCCCTCTCCTGTTCCCTGTTCCAAGTCCCCTGCA 2561 CTGACCTTTCTTGAGTCTCTCTGGCTCTGTGCATGTCTTTGGGACTCTGCTCATCTGGCTTTTCCTCTGTGTGTGCCTCT 2641 CTGTTTGCTTATGTCTCTGGCTCTGTCTTCCCCACCCCTCCCCTCACACACACACATACTCCCAAATGTAAGGCTCTGTG 2721 GCAGGTTGGAATCGGAGTAAGGCTTGAGATTCACTGAGTTCTGTAGGTAGGGAAAGAAGTCAAGGGAGTGGAGGTTCTAT 2801 AAGGAATTAACAGCTGAGGACGGAAGGGTTTGTTTCCCGTTTGAACCTAAACGCAAGTGGAAAAGAATACTCAGAATGTA 2881 TTTTTCTACTTTACATCTGCTGGGGAAGGAAATGTGTCAGGAAGCCGCTGCATCTGGTCATTTCATCGCATCAGAATCAC 2961 AGCAGACGTGGAAGATTCCATGTGGTGGGGAATAAAGAAATAACTTTATGCTCTCCTGAAAAACAGCGGGAGCCTATGTG 3041 TGTGTGCGACACTGTAATCTCAAGGAGATTCACTCAGAGCTGTCTCAGTCCAACTCCTGCATGACCAGATCTTCCCTTAG 3121 CATCTTTTCTGTGATGAAATATTATCTTGTGTTAGAGTTAGGAATAGGAACTAACCTGTAGGAGCATGTCCCCAAATGGA 3201 CATTTGAATGGACTAACAAAAACAACTGGAAAGACTGAATTTCCGACACAAAGGAATGATGGGATCAAAAAGAAAGCAGT 3281 GAGGAGTTCTTGAGTCTTGTAGTACCTATTCTTATTTTAACTTGCTTCATCCTTGATCTACCTGAGACACTAAGAAGGAA 3361 ATTAGTTTTCCAAGAGCTCTTTGAACCTGTCTAGGACTGTAGTTAAACCTATTTGCCCTATGGGGGTTCTTCACACTCGA 3441 AAAACTATTTCCTTATCACCAACGACCCACCCAGAAAGGCCAATGAGGCCAAATGTAACAATTTTTAACATTTAAATATA 3521 ACTATTAAAATTGCATTAATTGTGAACAGTGAATTAAAGGGTTGTCTTCTCCAGGAGACAGTATGTGGCACTTTTCGTAA 3601 ATTTCATTTAATATATAAAAATTTAAATCACTCACTGCAACATGCATTTAAAATCTTCCAAGAAGGTAGAGGTATCATTT 3681 TCTGTTTTGCTTTGTTTTAAAACAGTTGCCTCAAGCTTCTGTCTTAAGAGTAGTGACTTAGAATCCAGATATCTTTTGTT 3761 TTAGAAAAACAAGCAAAACTATGTTGCAAGACTGACAGTTGTAATGTTTATTTGCCACAGATCAAAGGTTCACAAAGTAT 3841 ATCAAATTTACATCTACTTGGGGTACCTTGATAGATTATTATTGTTTTTCTTTTATCTTTCCCTTCAGGAATTTGGAAAC 3921 TCGTTGTCACTTTTTTTAATTTTAAAAATACTAAATTGTAATAGTTTTCTTTTGCCAAATGTGTGCGTACATATTCAAAG 4001 CAATGAAACTATTTCAAGCCATACAACCACAGGGGTGGGAACCCTTTTCACAAATTTTAATGTGTTTGTATGTAAATAGA 4081 TGTTTGTATGAAATATTTTCATGATAGAATGAATATATTTAAATGAAGTTGAATTATTCCAGTGCTACTTAAACACATTA 4161 CAAAAATTTTGGTGAGAATTATCTGAGTCTATTGAGATGTAATGCAGATCAATTTTGATTTTTAAAAATCAAAAGCCTAC 4241 AATAACTCTGACTCTCAGCAACTTCCTCGGCGTTGTTGCACCTGACGTGGAGAGAGCTCGTAGGCTTCCCCAGTGCCTCA 4321 GCCGCTTCCTGGTGGAAGTTAGGTGCTAATGGAGGTGTGTTCACCTTTTAGTGATATCACTGCAGGCCTTTGAGGGGCCT 4401 GAGAGTGAATCAGAGGCATTAGAGACACCGGTGCAGTTATCTGGAGCACAATTTCTTTGCAGGGCAGCAGAATCAGAAGC 4481 CAGACTTGGCCATGTGAACCTCGAAACTCGGTTTCCCGGCCGCCATCAACCGCCACCCTTACTGCCTAGTCACACACGTC 4561 AGGGAGGCTGCCCTCAGTGGAGTTGGGGTTGAGACCCCAGGGTGGGACTTCACAGTTTTGCCAGCAATCTCTACCTTCTG 4641 ACTTCTGCCTCGCAGAGAGGAAGGAGAGGGGAGCATCTGGCAAGGGGCCCATTTCTCAGCACAGTACATTTCCTGTCTCA 4721 GCTCTGGAAGACTATGCACCCAAGCACCAAACTTCCAACCAGAGAGAGAGACGTCCTCCGATAACAAAAATCCTTGCTTC 4801 CTCTGTCTGTGACTTTACACACAGTTGTTCAAAGTTGTTAAATGTCAAGAGTCAATCACATCCCTAGGACATACCTCCCA 4881 ACTCTCCTGACTCTTATGTTATTGAAAAAACAAACAAACAAAAACTCCTTTATGATGATATTCAACTTGAGTGGGGTTTT 4961 TTTTCCACTTTGGTCCTGGATATAATGAAATGATACATATTAGGATAAATTTTCACTGTGTATAGTAGCAATACGAACAC 5041 ACATGCCAATGTATCAACATATCTACTTGGTTACATTTTGGTTTATGATAATTAACCTTGATTCATGTATTGGGAAGCTA 5121 CAGGGACTACGTAATACCTGCTTATCACATAGGAAAATTATGTCCATGATTCTGAGCTCCCTTCTTCAAAAGTTTCCTCC 5201 TGGGTGTTCTATGTTCTCTCTTTATCCTGAAATACATTTATTAGGTTGTGAGGTATGTTGAAGAAGTAGAAGCCAGGGGT 5281 ATGCTTTCAGCATTTATTGCAACCAAAAGTTAACCCCATCACGGTTAACGAGCATCTTTGGTCTCTTGTGGAATTTGAAC 5361 TAAAACTATGAGCCTTATTCAATATCTATAATTCTATGATTTTTTTAAATTATGGGAAATTAATGAAAGATGTTTACATG 5441 AATAATGTTTGCCCTTACTGTGTTATGAATGAGTTTTTTGTAGTGTGTCTGGGTGCATGATGCAAGAGAGTAGGAAAAAT 5521 GTTTCTGAAACAAAACTTGACAAATATTTGTAATGAAAGTAAATTTAAAGATTGCTATAATTGCGCTATAGAAACAATGC 5601 AAGTATTAAACAAAATATACAATCAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Flp-In T-REx 293-hAGO1 cells | ||||||
Location of target site | 3'UTR | ||||||
Original Description (Extracted from the article) |
...
Validation of interactions identified by CLASH suppports their reliability.
... - Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Helwak A; Kudla G; Dudnakova T; Tollervey D - Cell, 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [PMID: 23622248]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
82 hsa-miR-28-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000595 | CDKN1A | cyclin dependent kinase inhibitor 1A | 4 | 1 | ||||||||
MIRT006402 | MPL | MPL proto-oncogene, thrombopoietin receptor | 3 | 1 | ||||||||
MIRT006411 | N4BP1 | NEDD4 binding protein 1 | 1 | 1 | ||||||||
MIRT006414 | OTUB1 | OTU deubiquitinase, ubiquitin aldehyde binding 1 | 1 | 1 | ||||||||
MIRT006416 | TEX261 | testis expressed 261 | 1 | 1 | ||||||||
MIRT006418 | MAPK1 | mitogen-activated protein kinase 1 | 1 | 1 | ||||||||
MIRT006419 | E2F6 | E2F transcription factor 6 | 1 | 1 | ||||||||
MIRT049989 | ZCCHC3 | zinc finger CCHC-type containing 3 | 1 | 1 | ||||||||
MIRT049990 | TPM4 | tropomyosin 4 | 1 | 1 | ||||||||
MIRT049991 | TULP4 | tubby like protein 4 | 1 | 1 | ||||||||
MIRT049992 | SNX1 | sorting nexin 1 | 1 | 1 | ||||||||
MIRT049993 | IMPDH1 | inosine monophosphate dehydrogenase 1 | 1 | 1 | ||||||||
MIRT049994 | AAAS | aladin WD repeat nucleoporin | 1 | 1 | ||||||||
MIRT049995 | CENPV | centromere protein V | 1 | 1 | ||||||||
MIRT049996 | NRN1 | neuritin 1 | 1 | 1 | ||||||||
MIRT049997 | GEMIN4 | gem nuclear organelle associated protein 4 | 1 | 1 | ||||||||
MIRT049998 | ZBTB47 | zinc finger and BTB domain containing 47 | 1 | 1 | ||||||||
MIRT049999 | UNG | uracil DNA glycosylase | 1 | 1 | ||||||||
MIRT050000 | CNN3 | calponin 3 | 1 | 1 | ||||||||
MIRT050001 | KLHL12 | kelch like family member 12 | 1 | 1 | ||||||||
MIRT050002 | TLK1 | tousled like kinase 1 | 1 | 1 | ||||||||
MIRT050003 | SREBF2 | sterol regulatory element binding transcription factor 2 | 4 | 1 | ||||||||
MIRT050004 | RAB36 | RAB36, member RAS oncogene family | 1 | 1 | ||||||||
MIRT050005 | ZNF106 | zinc finger protein 106 | 1 | 1 | ||||||||
MIRT050006 | SETD7 | SET domain containing lysine methyltransferase 7 | 1 | 1 | ||||||||
MIRT050007 | DENND4B | DENN domain containing 4B | 1 | 1 | ||||||||
MIRT050008 | CS | citrate synthase | 1 | 1 | ||||||||
MIRT050009 | CD276 | CD276 molecule | 1 | 1 | ||||||||
MIRT050010 | TUFM | Tu translation elongation factor, mitochondrial | 1 | 1 | ||||||||
MIRT050011 | SMYD1 | SET and MYND domain containing 1 | 2 | 5 | ||||||||
MIRT050012 | SIK1 | salt inducible kinase 1 | 1 | 1 | ||||||||
MIRT054748 | MAD2L1 | mitotic arrest deficient 2 like 1 | 3 | 1 | ||||||||
MIRT054749 | BAG1 | BCL2 associated athanogene 1 | 3 | 1 | ||||||||
MIRT054750 | RAP1B | RAP1B, member of RAS oncogene family | 3 | 1 | ||||||||
MIRT317835 | CCND3 | cyclin D3 | 2 | 2 | ||||||||
MIRT367642 | ARHGAP42 | Rho GTPase activating protein 42 | 2 | 4 | ||||||||
MIRT443876 | DDTL | D-dopachrome tautomerase like | 2 | 2 | ||||||||
MIRT447544 | RNF165 | ring finger protein 165 | 2 | 2 | ||||||||
MIRT447611 | PCYOX1 | prenylcysteine oxidase 1 | 2 | 2 | ||||||||
MIRT447838 | CTIF | cap binding complex dependent translation initiation factor | 2 | 2 | ||||||||
MIRT448193 | FAM168A | family with sequence similarity 168 member A | 2 | 2 | ||||||||
MIRT448713 | KLHL11 | kelch like family member 11 | 2 | 2 | ||||||||
MIRT450179 | KLF7 | Kruppel like factor 7 | 2 | 2 | ||||||||
MIRT450312 | DRAXIN | dorsal inhibitory axon guidance protein | 2 | 2 | ||||||||
MIRT460792 | VPS37B | VPS37B, ESCRT-I subunit | 2 | 2 | ||||||||
MIRT466332 | THRA | thyroid hormone receptor, alpha | 2 | 2 | ||||||||
MIRT467610 | SLC7A5 | solute carrier family 7 member 5 | 2 | 2 | ||||||||
MIRT471609 | PAQR5 | progestin and adipoQ receptor family member 5 | 2 | 2 | ||||||||
MIRT472144 | NKIRAS2 | NFKB inhibitor interacting Ras like 2 | 2 | 4 | ||||||||
MIRT476588 | G3BP1 | G3BP stress granule assembly factor 1 | 2 | 4 | ||||||||
MIRT486265 | LINC00346 | long intergenic non-protein coding RNA 346 | 2 | 4 | ||||||||
MIRT486480 | TSC22D1 | TSC22 domain family member 1 | 2 | 2 | ||||||||
MIRT487978 | IQSEC2 | IQ motif and Sec7 domain 2 | 2 | 2 | ||||||||
MIRT489428 | TUBB2A | tubulin beta 2A class IIa | 2 | 2 | ||||||||
MIRT500781 | TMED4 | transmembrane p24 trafficking protein 4 | 2 | 6 | ||||||||
MIRT501235 | SEMA4C | semaphorin 4C | 2 | 6 | ||||||||
MIRT511045 | NRF1 | nuclear respiratory factor 1 | 2 | 2 | ||||||||
MIRT512837 | IER3 | immediate early response 3 | 2 | 2 | ||||||||
MIRT513091 | USP9X | ubiquitin specific peptidase 9, X-linked | 2 | 2 | ||||||||
MIRT513543 | PRDM2 | PR/SET domain 2 | 2 | 4 | ||||||||
MIRT532391 | UMPS | uridine monophosphate synthetase | 2 | 2 | ||||||||
MIRT535846 | MSI2 | musashi RNA binding protein 2 | 2 | 2 | ||||||||
MIRT537892 | EDA2R | ectodysplasin A2 receptor | 2 | 2 | ||||||||
MIRT552769 | YIPF6 | Yip1 domain family member 6 | 2 | 2 | ||||||||
MIRT553549 | TMEM167A | transmembrane protein 167A | 2 | 4 | ||||||||
MIRT557228 | HNRNPC | heterogeneous nuclear ribonucleoprotein C (C1/C2) | 2 | 2 | ||||||||
MIRT566756 | MORF4L1 | mortality factor 4 like 1 | 2 | 2 | ||||||||
MIRT567505 | FOXJ3 | forkhead box J3 | 2 | 2 | ||||||||
MIRT568165 | CCDC6 | coiled-coil domain containing 6 | 2 | 2 | ||||||||
MIRT570263 | PRSS16 | protease, serine 16 | 2 | 2 | ||||||||
MIRT614727 | TEAD3 | TEA domain transcription factor 3 | 2 | 2 | ||||||||
MIRT668894 | CRISPLD2 | cysteine rich secretory protein LCCL domain containing 2 | 2 | 2 | ||||||||
MIRT691021 | CRTC3 | CREB regulated transcription coactivator 3 | 2 | 2 | ||||||||
MIRT697421 | ZFP91 | ZFP91 zinc finger protein | 2 | 2 | ||||||||
MIRT711474 | SRD5A1 | steroid 5 alpha-reductase 1 | 2 | 2 | ||||||||
MIRT720189 | CMC4 | C-X9-C motif containing 4 | 2 | 2 | ||||||||
MIRT720622 | PIANP | PILR alpha associated neural protein | 2 | 2 | ||||||||
MIRT731420 | IGF1 | insulin like growth factor 1 | 3 | 1 | ||||||||
MIRT732850 | LINC00265 | long intergenic non-protein coding RNA 265 | 3 | 0 | ||||||||
MIRT732851 | PCNA | proliferating cell nuclear antigen | 3 | 0 | ||||||||
MIRT736342 | FOXO1 | forkhead box O1 | 3 | 0 | ||||||||
MIRT755341 | YWHAZ | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta | 3 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|